TBI-based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with ALL. We investigated toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide and cyclophosphamide for ALL within a prospective study. Major inclusion criteria were CR and non-eligibility for TBI. Fifty patients with a median age of 46.5 years (range, 18-64) were included. Donors were HLA-identical sibling (n = 8), matched (n = 42) or mismatched (n = 10) unrelated. The toxicity was moderate, resulting in a cumulative incidence of non-relapse mortality (NRM) at 1 year of 8% (90% confidence interval: 2-15%). Acute GvHD grade II-IV and grade III/IV was noted in 53% and 14%, respectively. Chronic GvHD at one year was seen in 41%. After a median follow-up of 24 months the cumulative incidence of relapse was 36% (90% confidence interval: 24-48) and 51% (90% confidence interval: 37-65) at 1 and 2 years, respectively. The estimated 2-year disease-free and overall survivals were 36 and 48%, respectively. Treosulfan, etoposide and cyclophosphamide followed by AHSC has a favorable toxicity profile with low NRM and therefore represents a potential alternative regimen for ALL in 1. CR (NCT00682305).
INTRODUCTION
ALL is a hematological malignancy characterized by rapid proliferation and subsequent accumulation of immature lymphocytes. Acute lymphoblastic leukemia accounts for~20% of all acute leukemia seen in adults older than 20 years. Over the past decade, there has been substantial improvement in treatment of adult patients with acute lymphoblastic leukemia. [1] [2] [3] With modern intensified chemotherapy,~30% of the adult patients can achieve a cure of their disease. High-dose chemotherapy or high-chemoradiotherapy followed by allogeneic stem cell transplantation (AHSC) has resulted in a long-term disease-free survival (DFS) in some patients with advanced or relapsed disease and has been successfully utilized in patients with high-risk disease transplanted in first remission. [4] [5] [6] A benefit for allogeneic transplantation in comparison with chemotherapy with autologous transplantation was confirmed. 7 In this study, the beneficial effect was more frequently seen in patients with high-risk acute leukemia with a DFS of 44% in the allografting group in comparison with 11% in the group with chemotherapy or autologous transplantation. The International Bone Marrow Transplant Registry reported a DFS of 42% for those patients who received an allogeneic transplantation in second CR. 8 Recent data suggest that unrelated transplantation resulted in similar outcome in comparison with related donors. 9, 10 The major limiting factor for the application of AHSC for ALL patients is the relatively high treatment-related mortality, which exceeded 30% in most of the studies. 9, 10 This high treatment-related mortality can be caused in part by intensified regimen including TBI. The most commonly used regimen for transplantation of patients with acute lymphoblastic leukemia is cyclophosphamide in combination with TBI. Some centers replaced etoposide for cyclophosphamide or added etoposide to cyclophosphamide in combination with TBI. 11 To reduce toxicity, investigators at Johns Hopkins University approached the problem by substituting busulfan for TBI to decrease the long-term side effects of TBI. 12 These non-radiation-dependent regimens showed activity in the treatment of ALL and suggest that TBI is not an absolute requirement for successful treatment of ALL by high-dose chemotherapy. However, in retrospective studies from International Bone Marrow Transplant Registry and Germany, the TBI-cyclophosphamide regimen was superior to the non-TBI-containing busulfan-based regimen. 10, 13 Hence, these data demonstrate a strong need to evaluate new drugs with a lower toxicity as conditioning regimen for patients with acute lymphoblastic leukemia. Treosulfan as part of the conditioning regimen might be an alternative to TBI-based regimens.
The present study was a multicentre, prospective phase II-study, investigating safety and efficacy of the combination of treosulfan, etoposide and cyclophosphamide as conditioning regimen for patients with acute lymphoblastic leukemia who are not eligible for a TBI-containing regimen.
PATIENTS AND METHODS

Patient's characteristics
Patients aged 18-60 were eligible for the study if they had acute lymphoblastic leukemia in first or subsequent CR and indication for AHSC according to the German Acute Lymphoblastic Leukemia Study Group. Furthermore, patients had to have an HLA-identical sibling or an HLA-A, -B, -C, -DRB1 and DQB1 compatible unrelated donor, allowing one Ag-mismatch. Patients had to be not eligible for TBI owing to either prior radiation of the spine 430 Gy, prior radiation of the mediastinum 430 Gy, severe encephalopathy during induction chemotherapy, decreased pulmonary function with diffusing capacity of lung for carbon monoxide o50%, or patient's wish to avoid TBI as conditioning regimen. Major exclusion criteria were absence of CR at registration, severe irreversible renal, hepatic, pulmonary or cardiac disease, and progressive invasive fungal infection at time of registration. The conditioning regimen consisted of treosulfan (12 g/m 2 ) given intravenously on three consecutive days (-7, -6 and -5) plus etoposide (30 mg/kg body weight) given intravenously on day -4, and cyclophosphamide (60 mg/kg body weight) given intravenously on day -3 and -2. GvHD prophylaxis consisted of ATG-Fresenius (Fresenius Biotech, Gräfelfing, Germany), 20 mg/kg given on day -3, -2 and -1 for unrelated donors, and optional for matched related donors. All patients received cyclosporine A and a short course of methotrexate. Cyclosporine A was to be started at a dose of 3 mg/kg body weight per day as continuous infusion, starting on day -1, according to the local standard policy, subsequently adjusted to blood level, which should be between 200 and 300 μg/L (monoclonal). Cyclosporine A was to be switched to oral application, 3 mg/kg b.i.d. when tolerating oral medications, in the absence of GvHD. When Cyclosporine A was switched orally the dose was to be maintained to target achieve a serum level of 200-300 mg. Cyclosporine A was tapered around day 120 in the case of no acute GvHD and was further tapered (25% every 2 weeks) to be discontinued at day 180, provided that there was no evidence of GvHD. Further dose reduction or withdrawal due to toxicity was to be performed according to the local policy. Methotrexate was to be given on day +1 at a dose of 15 mg/m 2 , and at a dose of 10 mg/ m 2 on day +3, day +6 and day +11 intravenously. In case of severe mucositis and high bilirubin level, the dose of methotrexate was to be adjusted according to the local policy.
Between July 2007 and August 2010, 50 patients were enrolled from 10 German centers. The patients' characteristics are listed in Table 1 . Primary objective of the study was engraftment on day 28, and non-relapse mortality (NRM) at day +100, and at 1 year. Secondary objectives were incidence of acute and chronic GvHD, DFS and overall survival at 2 years, toxicity according NCT-CTCAE v3.0, cumulative incidence of relapse at 2 years. All patients gave written informed consent, and the study was approved by the Ethics Committee of the German Health Authorities, and registered under NCT00682305, EudraCT: 2006-0035 66-34.
Infectious prophylaxis and supportive care
All patients received antibacterial prophylaxis with ofloxacin or ciprofloxacin until engraftment. Antiviral prophylaxis were given with acyclovir according to local policy, with cotrimoxacole twice weekly or alternatively monthly, and with inhalation with pentamidine up to 1 year after AHSC. Preemptive CMV-treatment with ganciclovir in case of documented viral reactivation, determined by pp65-test or PCR-technique. CMV-negative patients were to be transfused with CMV-negative blood products or with adequately fitting system. All blood products had to be irradiated. Antiemetic medication were given according to local practice or international guidelines. Fluid administration was done according to local policy.
Statistical methods and assessment criteria
Neutrophil engraftment was to be documented as the first of 3 consecutive days with an absolute neutrophilic granulocyte count of 40.5 × 10 9 /L in the peripheral blood. Leukocyte engraftment was to be documented by the first of 3 consecutive days with a total WBC count 41 × 10 9 /L in the peripheral blood. Platelet engraftment was to be documented by the first of 3 consecutive days with a platelet engraftment count of 420 × 10 9 /L and 450 × 10 9 /L in the absence of platelet transfusion.
NRM was defined as the P of dying in the absence of persisting disease or previous occurrence of relapse or graft failures. Persisting disease/ relapse was considered a competing event. Patients alive without relapse or persisting disease were censored at last contact.
Patients were considered to be experiencing an event when they had relapsed. Death without relapse and graft failures were competing risks. Patients alive with no history of relapse were censored at the time of last clinical examination of the disease status. Patients alive without relapse or persisting disease were censored at last contact. According to study protocol and the definition of relapse according to GALL protocol, the criteria to define CR were bone marrow showing o5% blasts (M 0 or M 1 ), no blasts in peripheral blood and no organ involvement.
Overall survival was defined as the P of survival irrespective of disease status at any point in time. Patients alive at their last follow-up were censored.
DFS was measured from time of start of stem cell transplantation ( = day 0) to time of event. Events were defined as relapse of disease, graft failure or death (whatever occurred first). Patients without relapse or persisting disease are censored at the last time without indication of relapse or persisting disease.
Chimerism studies by bone marrow and blood samples were performed prior to transplantation, following engraftment at day 28, day 100, at 6 months, and at 1 year after transplantation. Chimerism tests were performed either with variable number of tandem repeat regions, in sexmismatch-patients with FISH. Toxicity and GvHD Within 28 days after SCT, all patients suffered from at least one adverse event. In total, 2%, 2%, 66%, 28% and 2% of patients 
RESULTS
Between
Risk profile (according to GMALL) Standard risk n = 7 (14%) High risk n = 22 (44%) very high risk n = 21 (42%) Disease status at transplantation 1st CR n = 37 (74%) 2nd CR n = 11 (22%) 42nd CR n = 2 (4%) Donor type HLA-identical sibling n = 8 (16%) Matched unrelated donor n = 42 (84%) Mismatched unrelated donor n = 10 (20%)
Inclusion criteria
Prior radiation n = 9 (18%) Prior encephalopathy n = 2 (4%) DCLO o50% n = 15 (30%) Patient's wish n = 24 (48%)
Abbreviations: DCLO ¼ diffusing capacity of lung for carbon monoxide; GMALL ¼ German Acute Lymphoblastic Leukemia Study Group.
Treosulfan-based conditioning for ALL N Kröger et al suffered from maximum common toxicity criteria (CTC) grades I, II, III, IV and V, respectively. Focusing on those adverse events that were judged to be at least possibly related to the conditioning regimen, the respective worst grades were 6, 10, 64, 20 and 0%, respectively. The most frequent adverse events were of CTC category 'gastrointestinal' (98%), followed by 'infection' (80%), 'metabolic/ laboratory' (52%), 'cardiac general' (50%), 'pain' (48%), 'dermatology/skin' (46%) and 'pulmonary/upper respiratory' (40%). All other CTC categories were documented in o40% of study patients.
Among the gastrointestinal adverse events, mucositis/stomatitis occurred most often (82%), followed by diarrhea in 44% of patients and nausea in 26% of patients. Among the category 'infection', infections with grade III-IV neutropenia were most frequent (34%), whereas hyperbilirubinemia was most often documented in the CTC category 'metabolic/laboratory' (28%). Focusing on grade III/IV/V adverse events, 96% of patients experienced at least one event. In the CTC categories 'gastrointestinal' (72%), followed by CTC category 'infection' (62%), the leading events were mucositis/stomatitis (58%), and 'infection with grade III-IV neutrophils' (34%), respectively. Veno-occlusive disease was seen in four patients. Veno-occlusive disease was classified as mild (n = 3) and severe (n = 1)
The cumulative incidence of acute GvHD after transplantation was 53%. The cumulative incidence of grades III-IV acute GvHD after transplantation was 14%. The cumulative incidence of chronic GvHD at 24 months after transplantation was 41%. Focusing on extensive cGvHD only, revealed cumulative incidence of 14% at 24 months. In total, 26 severe adverse events were reported in 12 patients as listed in Table 2 . Within 28 days after SCT, 22% of patients were affected; 4% of patients suffered from grade III-severe adverse advent, and 18% patients from grade III-severe adverse advent. No unexpected severe adverse advent occurred. Haematological severe adverse events were excluded within the first 28 days after transplantation.
Engraftment and chimerism
The engraftment rates at day 28 were 88% for leukocytes, and 63% for platelets. On day 56 leukocyte engraftment was 96% and for platelets 84%. Three primary graft failures were observed, and one patient died due to graft failure. Overall, complete donortype chimerism could be achieved in 83% of patients at day 100.
Non-relapse mortality NRM at day 100 was 2% (90% confidence interval: 0-5%). One-year NRM rate was 8% (90% confidence interval: 2-15%) (see Figure 1) . As the upper limit of the confidence interval is statistically significant below 35% (one-sided P o 0.05), which was considered to be the benchmark for concluding that treosulfan might be promising in this indication at the design stage of this trial, at the end of follow-up (two years), the cumulative incidence of NRM increased to 16%. Infections were the major cause of death, one patient died to EBV-related lymphoma.
DFS and overall survival
The median DFS was 13.6 months, the 12-and 24-month rates were 56% and 36%, respectively. Patients in first CR experienced a median DFS of 25.7 months versus 8.9 months in patients beyond first CR. The 12-and 24-month DFS-rates were 69% and 50%, respectively, compared with 23% and 0%, respectively. Cumulative incidence of relapse was 36% (90% confidence interval: 37-65) after 12 months, and 51% (90% confidence interval: 37-65) after 24 months (see Figure 2) . Patients in first CR showed a 12-month relapse rate of 23% compared with 69% in patients beyond first CR. After 24 months, the respective rates were 34% compared with 92%. Kaplan-Meier estimates of overall survival were 74% after 12 months declining to 48% after 24 months (see Figure 3) . Median survival was 23.6 months. No difference within subgroups was observed.
DISCUSSION
Treosulfan (L-threitol-1,4-bis-methanesulphonate) is a bifunctional alkylating cytotoxic agent that has been approved in Germany for treatment of ovarian cancer. In preclinical models, antineoplastic activity of treosulfan against other malignancies has been shown including activity against acute lymphoblastic leukemia.
14 In human ALL-SCID-19 xenografts, antileukemic activity of treosulfan was demonstrated. 15, 16 Because of the limited non-hematological toxicity, treosulfan has been investigated for conditioning prior allogeneic transplantation. Treosulfan in combination with fludarabine or cyclophosphamide as conditioning regimen prior to AHSC has shown significant activity with a low toxicity profile in different hematological malignancies such as myelodysplastic syndromes and AML. [17] [18] [19] This prospective multicentre phase II-study investigated non-TBI-containing conditioning regimen containing treosulfan, etoposide and cyclophosphamide in patients with acute lymphoblastic leukemia in first or subsequent CR that were not eligible for TBI. Retrospective studies suggested a superiority of TBI in comparison with busulfan-conditioning regimen for patients with acute lymphoblastic leukemia who underwent AHSC. The International Bone Marrow Transplant Registry reported a 3-year survival of 55% for TBI-, and 40% for busulfan-containing regimens. 13 A German study, which included 264 patients with ALL also reported a superior DFS for patients who received TBI instead of busulfan as conditioning regimen prior to AHSC (30% vs 17%, P = 0.04). 9 Considering these retrospective data and realizing the medical need of a non-TBI conditioning regimen for patients with acute lymphoblastic leukemia, we investigated a treosulfanbased regimen (NCT00682305).
We observed engraftment at day 28 in 88% of the patients, and three patients experienced graft-failure. The toxicity profile was modest, resulting in low NRM at 1 and 2 years of 8% and 16%, respectively. Major cause of treatment failure was relapse in 36% at 1 year and 51% at 2 years, resulting in an overall survival at 2 years of 48%. The incidence of relapse at 2 years was higher in patients beyond first CR (92% vs 34%), which resulted in a 2-year overall survival of 51% for patients transplanted in first CR, and 38% for those beyond first CR. These results with respect to relapse and survival seem to be comparable to those reported from larger studies, which mainly used TBI-based conditioning regimens with relapse rates between 24% and 61, and 5-year survival between 38 and 54%. [20] [21] [22] [23] The TBI-containing myeloablative regimen developed at Stanford is considered the standard conditioning regimen for acute lymphoblastic leukemia; however, no randomized trials are available so far. Apart from acute toxicity, major concerns regarding TBI are long-term effects, such as secondary malignancies, which occurs more frequently after TBI-based regimens than after chemotherapy-based regimens. 24 To lower toxicity especially for older patients, reduced-intensity conditioning regimens have been developed. Several groups and international registries reported encouraging results of using reduced-intensity conditioning regimens for acute lymphoblastic leukemia prior to AHSC with comparable results to myeloablative regimens in a non-randomized comparison. [25] [26] [27] However, despite the benefit of lower NRM, there was a higher risk of relapse, 26, 27 suggesting the optimal conditioning regimen should have high intensity with low toxicity profile. A major prognostic factor for outcome after AHSC for ALL is the amount of minimal residual disease at time of transplantation, 28 ,29 which was not tested with our prospective study. Overall, we conclude that conditioning regimen containing treosulfan, etoposide and cyclophosphamide represents a potential alternative for patients with ALL in 1. CR who need AHSC but are not eligible for TBI. Patients with advanced disease might potentially benefit from alternative cytoredeductive strategies before AHSCT and potentially also from maintenance therapy.
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